Searching journal content for paraganglioma (as phrase) in full text.

Displaying results 1-10 of 147
For checked items
  1. Review:
    • Vincenzo Marotta,
    • Maria Chiara Zatelli,
    • Concetta Sciammarella,
    • Maria Rosaria Ambrosio,
    • Marta Bondanelli,
    • Annamaria A L Colao,
    • and Antongiulio Faggiano
    Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame Endocr Relat Cancer ERC-17-0269, doi:10.1530/ERC-17-0269 first published on 24 October 2017
    ..., including those arising from 80 the gastroenteropancreatic tract and the bronchopulmonary area, which represent the majority, but 81 also pheocromocytomas/paragangliomas, medullary thyroid carcinoma, Merkel cell carcinoma of 82 the skin, and (even if data are controversial) pituitary and parathyroid ~~~
  2. Research:
    • Amruta Ashtekar,
    • Danielle Huk,
    • Alexa Magner,
    • Krista La Perle,
    • Xiaoli Zhang,
    • José I Piruat,
    • José López-Barneo,
    • Sissy M Jhiang,
    • and Lawrence S Kirschner
    Sdhd ablation promotes thyroid tumorigenesis by inducing a stem-like phenotype Endocr Relat Cancer 24 (11) 579-591, doi:10.1530/ERC-17-0229 first published on 19 September 2017
    ...autosomal genes SDHA, SDHB, SDHC and SDHD. These genes are known tumor suppressors owing to their established connection to the syndrome of inherited pheochromocytoma (PHEO) and paraganglioma (PGL) (Bardella etal. 2011, Letouze etal. 2013). Genetic variants in SDHB and SDHD have been identified ~~~
  3. Research:
    • Trisha Dwight,
    • Aidan Flynn,
    • Kaushalya Amarasinghe,
    • Diana E Benn,
    • Richard Lupat,
    • Jason Li,
    • Daniel Cameron,
    • Annette Hogg,
    • Shiva Balachander,
    • Ida Lm Candiloro,
    • Stephen Wong,
    • Bruce G Robinson,
    • Anthony T Papenfuss,
    • Anthony J Gill,
    • Alexander Dobrovic,
    • Rodney J Hicks,
    • Roderick Clifton-Bligh,
    • and Richard William Tothill
    TERT structural rearrangements in metastatic pheochromocytomas Endocr Relat Cancer ERC-17-0306, doi:10.1530/ERC-17-0306 first published on 3 October 2017
    [email protected]. 26 27 Page 1 of 22 Accepted Preprint first posted on 3 October 2017 as Manuscript ERC-17-0306 Copyright 2017 by the Society for Endocrinology. Abstract 28 Pheochromocytomas (PC) and paragangliomas (PGL) are endocrine tumors for which the genetic and 29 clinico-pathological features of metastatic ~~~
  4. Research Letter:
    • Yilun Deng,
    • Shahida K Flores,
    • ZiMing Cheng,
    • Yuejuan Qin,
    • Robin C Schwartz,
    • Carl Malchoff,
    • and Patricia L M Dahia
    Molecular and phenotypic evaluation of a novel germline TMEM127 mutation with an uncommon clinical presentation Endocr Relat Cancer 24 (11) L79-L82, doi:10.1530/ERC-17-0359 first published on 30 August 2017
    ...disease and in PHEO-paraganglioma syndromes related to mutations in succinate dehydrogenase (SDH) subunit genes (Maher 2011, Dahia 2014). The clinical spectrum and the signaling consequences of TMEM127 mutations remain poorly defined, and it is not clear whether both tumors can be associated in families ~~~
  5. Review:
    • Maria Domenica Castellone and
    • Rosa Marina Melillo
    RET-mediated modulation of tumour microenvironment and immune response in MEN2 Endocr Relat Cancer ERC-17-0303, doi:10.1530/ERC-17-0303 first published on 20 September 2017
    ...paraganglioma (Krawczyk, et al. 2010) urothelial carcinoma (Kato, et al. 2017) RET fusions papillary thyroid carcinoma (PTC) (Grieco et al. 1990) lung adenocarcinoma (Kohno, et al. 2012; Lipson, et al. 2012) colon carcinoma (Lipson et al. 2012) myeloproliferative disorders (Ballerini, et al. 2012) R ~~~
  6. Thematic Review:
    • Rami Alrezk,
    • Fady Hannah-Shmouni,
    • and Constantine A Stratakis
    MEN4 and CDKN1B mutations: the latest of the MEN syndromes Endocr Relat Cancer 24 (10) T195-T208, doi:10.1530/ERC-17-0243 first published on 19 August 2017
    ..., pheochromocytoma and paraganglioma; PA, primary aldosteronism. T202Thematic Review R Alrezketal. MEN4 and CDKN1B mutations DOI: 10.1530/ERC-17-0243 http://.endocrinology-journals.org 2017 Society for Endocrinology Printed in Great Britain Published by Bioscientifica Ltd. 24:10 Primary hyperparathyroidism (PHPT ~~~
  7. Thematic Review:
    • Hermine Mohr and
    • Natalia S Pellegata
    Animal models of MEN1 Endocr Relat Cancer 24 (10) T161-T177, doi:10.1530/ERC-17-0249 first published on 25 July 2017
    ...studies so far have reported the engraftment of NETs but with rather low success rates. In a proof-of-concept study Powers etal. (2017) demonstrated for the first time, the successful engraftment of pheochromocytomas and paragangliomas in the NSG mouse model. Histological analysis proved the conservation ~~~
  8. Review:
    • Carole Guerin,
    • Pauline Romanet,
    • David Taieb,
    • Thierry Brue,
    • André Lacroix,
    • Frederic Sebag,
    • Anne Barlier,
    • and Frederic Castinetti
    Looking beyond the thyroid: advances in understanding of pheochromocytoma and hyperparathyroidism phenotypes in MEN2 and of non-MEN2 familial forms Endocr Relat Cancer ERC-17-0266, doi:10.1530/ERC-17-0266 first published on 5 September 2017
    ...etiologies of hereditary bilateral PHEO (table 1). A 54 similar review will be made for HPTH. 55 56 2. PHEOCHROMOCYTOMA IN MEN2 AND NON-MEN2 FAMILIAL FORMS 57 PHEO are neuroendocrine tumors arising from adrenal medulla cells. 58 Paragangliomas (PGL) originate form sympathetic or parasympathetic paraganglia ~~~
  9. Research:
    • Vanessa D'Antongiovanni,
    • Serena Martinelli,
    • Susan Richter,
    • Letizia Canu,
    • Daniele Guasti,
    • Tommaso Mello,
    • Paolo Romagnoli,
    • Karel Pacak,
    • Graeme Eisenhofer,
    • Massimo Mannelli,
    • and Elena Rapizzi
    The microenvironment induces collective migration in SDHB-silenced mouse pheochromocytoma spheroids Endocr Relat Cancer 24 (10) 555-564, doi:10.1530/ERC-17-0212
    ...Institutes of Health, Bethesda, Maryland, USA *(V DAntongiovanni and S Martinelli contributed equally to this work) Abstract Pheochromocytomas (Pheos) and paragangliomas (PGLs) are neuroendocrine tumors. Approximately 3040% of Pheos/PGLs are due to germline mutations in one of the susceptibility genes ~~~
  10. Commentary:
    • Rodrigo Almeida Toledo
    New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas Endocr Relat Cancer 24 (9) C9-C19, doi:10.1530/ERC-16-0479 first published on 30 June 2017
    ...2-alpha (HIF2). This commentary published in Endocrine-Related Cancer is based on the recognition of similar molecular drivers in ccRCC and the endocrine neoplasias pheochromocytomas and paragangliomas (PPGLs), ultimately leading to stabilization of HIFs. HIF-stabilizing mutations have been ~~~
For checked items

Search Results

Next 10 » New Search

Modify Results

Citation format:
Results / page:
Results order:

This search

  • Alert me when new articles matching this search are published
  • Download all citations on this page to my citation manager

New Articles: issue in progress

  1. December 2017, 24 (12)
  1. Current Issue
  1. Alert me to new issues of Endocrine-Related Cancer

Most